Teclistamab
Based on 1 publication(s) in Google Scholar
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.87%
- CAS. Nr.: 2119595-80-9
- Molecular Weight:143.64 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
CD3 & BCMA
In Vitro
Teclistamab (0.01-1000 nM, 48 h) induces T cell-mediated cytotoxicity with the EC50 values of 0.15 nM in H929 cells, 0.06 nM in MM.1R cell lines, and 0.45 nM in RPMI 8226 cell lines, respectively[1].
Teclistamab (0.01-1000 nM, 48 h) can bind CD138 + human BM monocytes in a dose-dependent manner and induces cytotoxicity of human BM monocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NSG mice infected with H929 cell lines[1]
-
Dosage:0.1 µg (0.005 mg/kg), 0.5 µg (0.025 mg/kg), or 1 µg (0.05 mg/kg)
-
Administration:i.v., on days 0, 3, 5, 7, and 10
-
Result:Completely inhibited tumor growth at doses of 0.5 and 1 μg, while no inhibition of tumor growth was observed at a dose of 0.1 μg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human CD3 epsilon/CD3e Protein (ECD, His Tag) can bind Teclistamab. The EC50 for this effect is 1.56 ng/mL. -
Immobilized Human BCMA Protein (ECD, His Tag) can bind Teclistamab. The EC50 for this effect is 0.18 ng/mL. -
Flow Cytometry analysis of K562 cells labelling BCMA (red) with Teclistamab (HY-P99392). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 lambda (HY-P99987, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Product Details
-
CAS. Nr. 2119595-80-9
-
Synonyms JNJ-7957; JNJ-64007957; Tecvayli
-
Molecular Weight 143.64 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 lambda
-
Recommend Isotype Controls
-
Format
-
Human IgG4 lambda
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
99.87%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)